trending Market Intelligence /marketintelligence/en/news-insights/trending/Jxt52uqrtVk8956anvw-0w2 content esgSubNav
In This List

AbbVie, Principia Biopharma terminate immunology collaboration

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise

Blog

Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises


AbbVie, Principia Biopharma terminate immunology collaboration

AbbVie Inc. and Principia Biopharma Inc. mutually agreed to end a collaboration for the development of potential drugs known as oral immunoproteasome inhibitors.

Under the 2017 agreement, the companies were partnering to conduct research and pre-clinical studies of the potential treatments for autoimmune and inflammatory disorders. AbbVie was meant to initiate clinical development and commercialize the compounds discovered from the partnership.

South San Francisco, Calif.-based Principia has reacquired the rights to the program, with the termination effective in March.